Jayex Technology Limited develops and provides healthcare industry service technologies and integrated dispensing automation systems for the pharmaceutical and healthcare sectors in Australia and the United Kingdom.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.025|
|52 Week High||AU$0.021|
|52 Week Low||AU$0.06|
|1 Month Change||0%|
|3 Month Change||-7.41%|
|1 Year Change||-34.21%|
|3 Year Change||13.64%|
|5 Year Change||-46.81%|
|Change since IPO||-91.53%|
Recent News & Updates
Is Jayex Technology (ASX:JTL) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
|JTL||AU Healthcare Services||AU Market|
Return vs Industry: JTL underperformed the Australian Healthcare Services industry which returned 46.5% over the past year.
Return vs Market: JTL underperformed the Australian Market which returned 24.4% over the past year.
Stable Share Price: JTL is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: JTL's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Jayex Technology Limited develops and provides healthcare industry service technologies and integrated dispensing automation systems for the pharmaceutical and healthcare sectors in Australia and the United Kingdom. It offers Jayex Connect platform, a cloud-based patient engagement platform, which allow users for appointment booking, patient calling, patient check-in, health messaging, and script management. Its products also include Jayex antimicrobial screen covers; and Enlighten, a patient check-in kiosk.
Jayex Technology Fundamentals Summary
|JTL fundamental statistics|
Is JTL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|JTL income statement (TTM)|
|Cost of Revenue||AU$4.04m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0097|
|Net Profit Margin||-48.50%|
How did JTL perform over the long term?See historical performance and comparison
Is Jayex Technology undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate JTL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate JTL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: JTL is unprofitable, so we can't compare its PE Ratio to the Global Healthcare Services industry average.
PE vs Market: JTL is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate JTL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: JTL is good value based on its PB Ratio (3.2x) compared to the AU Healthcare Services industry average (4.1x).
How is Jayex Technology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Jayex Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Jayex Technology performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: JTL is currently unprofitable.
Growing Profit Margin: JTL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: JTL is unprofitable, but has reduced losses over the past 5 years at a rate of 38.2% per year.
Accelerating Growth: Unable to compare JTL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: JTL is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (37.7%).
Return on Equity
High ROE: JTL has a negative Return on Equity (-124.7%), as it is currently unprofitable.
How is Jayex Technology's financial position?
Financial Position Analysis
Short Term Liabilities: JTL's short term assets (A$4.0M) do not cover its short term liabilities (A$6.2M).
Long Term Liabilities: JTL's short term assets (A$4.0M) exceed its long term liabilities (A$3.2M).
Debt to Equity History and Analysis
Debt Level: JTL's debt to equity ratio (262.6%) is considered high.
Reducing Debt: JTL's debt to equity ratio has increased from 0.03% to 262.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: JTL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: JTL has less than a year of cash runway if free cash flow continues to grow at historical rates of 16.6% each year.
What is Jayex Technology current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate JTL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate JTL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if JTL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if JTL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of JTL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jayex Technology has no CEO, or we have no data on them.
Experienced Management: JTL's management team is considered experienced (3.2 years average tenure).
Experienced Board: JTL's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.8%.
Jayex Technology Limited's employee growth, exchange listings and data sources
- Name: Jayex Technology Limited
- Ticker: JTL
- Exchange: ASX
- Founded: 2006
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: AU$6.231m
- Shares outstanding: 249.23m
- Website: https://www.jayex.com/en-au/
Number of Employees
- Jayex Technology Limited
- 17B Cribb Street
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 07:02|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.